BioVie Inc. (BIVI) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioVie Inc. on July 29, 2024, regarding a Special Meeting of stockholders held on the same date. The filing details the approval and implementation of a reverse stock split for the Company's Class A Common Stock.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on corporate governance actions and capital structure adjustments.
Material Changes
- Reverse Stock Split Approval: Stockholders authorized the Board to effect a reverse stock split at a ratio between 1-for-6 and 1-for-10.
- Board Action: The Board exercised this authority to approve a one-for-ten (1:10) reverse stock split.
- Effective Date: The split becomes effective at 12:01 am Eastern Time on August 6, 2024.
- Share Reclassification: Every 10 pre-split shares will be reclassified into 1 post-split share. No fractional shares will be issued; holders entitled to fractions will receive one full share.
- Derivative Adjustments: Outstanding stock options, restricted stock units, and warrants will be adjusted proportionally, with exercise prices increasing accordingly.
- Trading Details: Trading will resume on The Nasdaq Capital Market on a split-adjusted basis with a new CUSIP number: 09074F405.
Voting Results
At the Special Meeting, stockholders voted on the following matters:
| Proposal | For | Against | Abstain |
|---|---|---|---|
| Authority to Effect Reverse Stock Split | 39,393,584 | 3,204,131 | 204,190 |
| Adjourn Special Meeting | 39,461,343 | 3,164,218 | 176,344 |
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the standard mechanics of the stock split. The primary contingency noted is the administrative process managed by West Coast Stock Transfer, Inc., as the exchange agent.
Key Facts for Investor Verification
- Verify the new CUSIP number (09074F405) for trading purposes starting August 6, 2024.
- Confirm the adjustment of exercise prices and share counts for any held options, RSUs, or warrants.
- Check brokerage statements to ensure fractional shares were rounded up to one full share as per the Company's policy.
- Monitor the post-split share price and trading volume on The Nasdaq Capital Market.